ProPhase Labs, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
ProPhase Labs, Inc. (PRPH) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$6.26 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-05-10
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$6.26M, a 1127.05% decline year-over-year.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$8.75M.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$5.14M, a 539.78% decline year-over-year.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$3.44M, a 144.99% decline year-over-year.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$16.78M, a 187.89% decline from fiscal 2022.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $19.09M, a 162.55% increase from fiscal 2021.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was $7.27M.
- ProPhase Labs, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$2.13M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2024-03-31 | -$6.26M 10-Q · filed 2024-05-10 | -$15.02M derived: sum of 2 quarters · filed 2024-05-10 | -$20.16M derived: sum of 3 quarters · filed 2024-05-10 | -$23.60M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-12-31 | -$8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$13.89M derived: sum of 2 quarters · filed 2024-03-29 | -$17.33M derived: sum of 3 quarters · filed 2024-03-29 | -$16.78M 10-K · filed 2024-03-29 | |
| 2023-09-30 | -$5.14M 10-Q · filed 2023-11-13 | -$8.58M derived: sum of 2 quarters · filed 2023-11-13 | -$8.03M 10-Q · filed 2023-11-13 | -$10.42M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-06-30 | -$3.44M 10-Q · filed 2023-08-11 | -$2.89M 10-Q · filed 2023-08-11 | -$5.28M derived: sum of 3 quarters · filed 2024-05-10 | -$4.11M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2023-03-31 | $610.00K 10-Q · filed 2024-05-10 | -$1.84M derived: sum of 2 quarters · filed 2024-05-10 | -$668.00K derived: sum of 3 quarters · filed 2024-05-10 | $6.98M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.28M derived: sum of 2 quarters · filed 2024-03-29 | $6.37M derived: sum of 3 quarters · filed 2024-03-29 | $19.09M 10-K · filed 2024-03-29 | $19.10M 10-K · filed 2023-03-29 |
| 2022-09-30 | $1.17M 10-Q · filed 2023-11-13 | $8.81M derived: sum of 2 quarters · filed 2023-11-13 | $21.54M 10-Q · filed 2023-11-13 | $32.95M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $7.65M 10-Q · filed 2023-08-11 | $20.37M 10-Q · filed 2023-08-11 | $31.78M derived: sum of 3 quarters · filed 2023-08-11 | $27.80M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $12.73M 10-Q · filed 2023-05-12 | $24.14M derived: sum of 2 quarters · filed 2023-05-12 | $20.16M derived: sum of 3 quarters · filed 2023-05-12 | $18.76M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $11.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $7.43M derived: sum of 2 quarters · filed 2023-03-29 | $6.04M derived: sum of 3 quarters · filed 2023-03-29 | $7.27M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$3.98M 10-Q · filed 2022-11-10 | -$5.37M derived: sum of 2 quarters · filed 2022-11-10 | -$4.14M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$1.40M 10-Q · filed 2022-08-12 | -$338.00K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $1.06M 10-Q · filed 2022-05-13 | ||||
| 2020-12-31 | -$2.13M 10-K · filed 2022-03-31 | ||||
| 2016-09-30 | $167.00K 10-Q · filed 2016-11-14 | -$960.00K derived: sum of 2 quarters · filed 2016-11-14 | -$2.30M 10-Q · filed 2016-11-14 | -$3.55M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2016-06-30 | -$1.13M 10-Q · filed 2016-08-11 | -$2.46M 10-Q · filed 2016-08-11 | -$3.72M derived: sum of 3 quarters · filed 2016-08-11 | -$3.12M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2016-03-31 | -$1.34M 10-Q · filed 2016-05-13 | -$2.59M derived: sum of 2 quarters · filed 2016-05-13 | -$1.99M derived: sum of 3 quarters · filed 2016-11-14 | -$3.56M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | -$654.00K derived: sum of 2 quarters · filed 2016-11-14 | -$2.22M derived: sum of 3 quarters · filed 2016-11-14 | -$3.60M 10-K · filed 2016-03-29 | |
| 2015-09-30 | $602.00K 10-Q · filed 2016-11-14 | -$964.00K derived: sum of 2 quarters · filed 2016-11-14 | -$2.34M 10-Q · filed 2016-11-14 | -$3.02M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-06-30 | -$1.57M 10-Q · filed 2016-08-11 | -$2.95M 10-Q · filed 2016-08-11 | -$3.62M derived: sum of 3 quarters · filed 2016-08-11 | -$6.84M derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | -$1.38M 10-Q · filed 2016-05-13 | -$2.06M derived: sum of 2 quarters · filed 2016-05-13 | -$5.27M derived: sum of 3 quarters · filed 2016-05-13 | -$8.41M derived: sum of 4 quarters · filed 2016-05-13 | |
| 2014-12-31 | -$676.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | -$3.89M derived: sum of 2 quarters · filed 2016-03-29 | -$7.03M derived: sum of 3 quarters · filed 2016-03-29 | -$7.83M 10-K · filed 2016-03-29 | |
| 2014-09-30 | -$3.22M 10-Q · filed 2015-11-13 | -$6.35M derived: sum of 2 quarters · filed 2015-11-13 | -$7.16M 10-Q · filed 2015-11-13 | -$6.56M derived: sum of 4 quarters · filed 2016-03-29 | |
| 2014-06-30 | -$3.14M 10-Q · filed 2015-08-12 | -$3.94M 10-Q · filed 2015-08-12 | -$3.34M derived: sum of 3 quarters · filed 2016-03-29 | -$2.11M derived: sum of 4 quarters · filed 2016-03-29 | |
| 2014-03-31 | -$804.00K 10-Q · filed 2015-05-13 | -$206.00K derived: sum of 2 quarters · filed 2016-03-29 | $1.03M derived: sum of 3 quarters · filed 2016-03-29 | -$689.00K derived: sum of 4 quarters · filed 2016-03-29 | |
| 2013-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $1.83M derived: sum of 2 quarters · filed 2016-03-29 | $115.00K derived: sum of 3 quarters · filed 2016-03-29 | $405.00K 10-K · filed 2016-03-29 | |
| 2013-09-30 | $1.24M 10-Q · filed 2014-11-13 | -$483.00K derived: sum of 2 quarters · filed 2014-11-13 | -$193.00K 10-Q · filed 2014-11-13 | $259.00K derived: sum of 4 quarters · filed 2015-03-27 | |
| 2013-06-30 | -$1.72M 10-Q · filed 2014-08-12 | -$1.43M 10-Q · filed 2014-08-12 | -$977.00K derived: sum of 3 quarters · filed 2015-03-27 | $97.00K derived: sum of 4 quarters · filed 2015-03-27 | |
| 2013-03-31 | $290.00K 10-Q · filed 2014-05-12 | $742.00K derived: sum of 2 quarters · filed 2015-03-27 | $1.82M derived: sum of 3 quarters · filed 2015-03-27 | -$114.00K derived: sum of 4 quarters · filed 2015-03-27 | |
| 2012-12-31 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.53M derived: sum of 2 quarters · filed 2015-03-27 | -$404.00K derived: sum of 3 quarters · filed 2015-03-27 | -$1.09M 10-K · filed 2015-03-27 | $1.09M 10-K · filed 2013-03-28 |
| 2012-09-30 | $1.07M 10-Q · filed 2013-11-13 | -$856.00K derived: sum of 2 quarters · filed 2013-11-13 | -$1.54M 10-Q · filed 2013-11-13 | -$3.38M derived: sum of 4 quarters · filed 2014-03-27 | |
| 2012-06-30 | -$1.93M 10-Q · filed 2013-08-13 | -$2.62M 10-Q · filed 2013-08-13 | -$4.45M derived: sum of 3 quarters · filed 2014-03-27 | -$3.34M derived: sum of 4 quarters · filed 2014-03-27 | |
| 2012-03-31 | -$688.00K 10-Q · filed 2013-05-10 | -$2.52M derived: sum of 2 quarters · filed 2014-03-27 | -$1.41M derived: sum of 3 quarters · filed 2014-03-27 | -$2.38M derived: sum of 4 quarters · filed 2014-03-27 | |
| 2011-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$723.00K derived: sum of 2 quarters · filed 2014-03-27 | -$1.70M derived: sum of 3 quarters · filed 2014-03-27 | -$2.71M 10-K · filed 2014-03-27 | $2.71M 10-K · filed 2013-03-28 |
| 2011-09-30 | $1.11M 10-Q · filed 2012-11-14 | $136.00K derived: sum of 2 quarters · filed 2012-11-14 | -$877.00K 10-Q · filed 2012-11-14 | ||
| 2011-06-30 | -$974.00K 10-Q · filed 2012-08-13 | -$1.99M 10-Q · filed 2012-08-13 | |||
| 2010-12-31 | $3.50M 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |